DMA-155 

DMA-155 is an antiviral agent with binding activity against SARS-CoV-2 5'-terminal stem-loop RNAs, with affinities of 51.1 μM (SL1), 61.1 μM (SL4), 54.5 μM (SL5a), 66.9 μM (SL5b) and 48.6 μM (SL6), respectively. DMA-155 inhibits SARS-CoV-2 viral replication and reduces SARS-CoV-2 viral RNA levels. DMA-155 is applicable to the research of COVID-19^[1].

DMA-155 (50-100 μM; 24 h) significantly inhibits human coronavirus OC43 replication in Vero E6 cells when administered at 50 μM or 100 μM for 24 hours^[1].
DMA-155 (24-72 h) potently inhibits SARS-CoV-2 replication in Vero E6 cells with an IC₅₀ of 16 μM at 24 hours post-infection, with sustained dose-dependent activity through 72 hours^[1].
DMA-155 (10 μM; 72 h) inhibits SARS-CoV-2 replication in Vero E6 cells at 10 μM for 72 hours without significant cellular toxicity^[1].
DMA-155 (0.1-100 μM; 2 days) specifically inhibits SARS-CoV-2 5'-UTR-dependent translation in Vero E6 cells, with a ~90% reduction in FLuc activity at 10 μM after 2 days of incubation, without non-specific effects on translation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

375.43

C₂₀H₂₁N₇O

2237925-69-6

O=C(C1=C(N)N=C(N(C)C)C(C2=CC=C(C3=CC=CC=C3)C=C2)=N1)NC(N)=N

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Amanda HARGROVE, et al. Amiloride derivatives and methods of using same for the treatment of viral infections. WO2022120150A1.